论文部分内容阅读
目的研究血必净注射液联合头孢曲松钠治疗肝硬化并原发性腹膜炎(SBP)的临床疗效。方法 85例肝硬化合并原发性腹膜炎患者,随机分为对照组(40例)和治疗组(45例)。对照组用注射用头炮曲松钠静脉滴注2.0 g,1次/d;治疗组用注射用头孢曲松钠静脉注射1次/d,加用血必净注射液50 ml,静脉滴注2次/d,连续用10 d。观察并记录两组患者治疗前后疗效及并发症发生情况。结果治疗组治疗总有效率高于对照组(P<0.05);并发症的发生明显少于对照组(P<0.05)。结论血必净联合头孢曲松治疗原发性腹膜炎临床效果明显,在临床可以推广应用。
Objective To study the clinical efficacy of Xuebijing injection combined with ceftriaxone in the treatment of cirrhosis and primary peritonitis (SBP). Methods Eighty-five patients with cirrhosis and primary peritonitis were randomly divided into control group (n = 40) and treatment group (n = 45). The control group with injection of the first gun warfarin sodium intravenous infusion of 2.0 g, 1 / d; treatment group with injection of ceftriaxone sodium intravenous injection 1 / d, plus Xuebijing injection 50 ml, intravenous infusion 2 times / d, continuous use of 10 d. Observed and recorded two groups of patients before and after treatment efficacy and complications. Results The total effective rate of the treatment group was higher than that of the control group (P <0.05). The incidence of complications was significantly less than that of the control group (P <0.05). Conclusion Xuebijing combined with ceftriaxone treatment of primary peritonitis clinical effect is obvious, it can be widely used in clinical practice.